Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy

Abstract

AbstractObjectiveGynecologic cancer chemotherapy impacts the quality of life (QOL) of patients, with lasting adverse events that may require treatment adjustments or discontinuation. Consequently, real‐time symptom monitoring before outpatient visits has resulted in improved QOL for patients and extended survival times. This study investigated whether there are differences between electronic patient‐reported outcomes (e‐PRO‐CTCAE) and physician‐assessed outcomes (NCI‐CTCAE) evaluated in an outpatient setting in gynecologic cancer chemotherapy.MethodsThe study was conducted on 50 patients who received their first chemotherapy treatment at St. Marianna University Hospital Obstetrics and Gynecology from July 1, 2021 to December 31, 2022. PRO‐CTCAE and NCI‐CTCAE were evaluated at each instance of chemotherapy and 2 weeks after. The PRO‐CTCAE was additionally collected weekly using e‐PRO.ResultsThe values for “Joint Pain,” “Nausea,” “Taste Disturbance,” “Constipation,” “Insomnia,” “Fatigue,” “Limb Edema,” and “Concentration Impairment” were consistently higher in PRO‐CTCAE than in NCI‐CTCAE, indicating that physicians underestimated the severity of adverse events. In contrast, there was no significant difference in “Peripheral Neuropathy,” demonstrating that physicians had a good understanding of this condition in patients. The weekly responses obtained from e‐PRO revealed that symptom exacerbations peaked outside of clinic visits.ConclusionsThis study demonstrated physicians tend to underestimate most adverse events. Moreover, the responses using e‐PRO revealed peak symptom deterioration occurred outside of outpatient visits. This suggested that e‐PRO and actions taken in response to them can improve patients' QOL.